Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis
Abstract
- °
- Infected pancreatic necrosis is a serious complication related to acute necrotizing pancreatitis and is related to high morbidity and mortality.
- °
- Antibiotic treatment combined with drainage/debridement through mini-invasive interventions is a key step in therapeutic management.
- °
- Although broad-spectrum antibiotics are often required as first-line therapy in suspected infected pancreatic necrosis, prolonged empirical use without microbiological guidance may contribute to the emergence of multidrug-resistant organisms.
- °
- This retrospective study included 71 patients with acute necrotizing pancreatitis, infected pancreatic necrosis (IPN), and walled-off necrosis (WON) having undergone minimally invasive interventions (endoscopy and radiology) for drainage (+/− debridement) with initial and subsequent documented bacteriological culture from the WON.
- °
- We revealed an increase in bacterial resistance during the treatment period: multidrug-resistant bacteria were already present at the first intervention in 27% of patients, extensively drug-resistant bacteria in 5.6%, and fungal infection in 30%, increasing to 35%, 15.5% and 59%, respectively, at the end of the treatment period.
- °
- Antibiotic changes and the need for nutritional support were independently associated with the emergence of multidrug-resistant bacteria in patients with IPN.
- °
- These findings support the use of antimicrobial stewardship initiatives aiming to rationalize antibiotic use and emphasize shorter, more targeted antibiotic therapy for patients with IPN.
1. Introduction
2. Results
2.1. Characteristics of the Population
2.2. Microbiological Culture and Antibiotics Before and After Intervention
2.3. Risk Factors Associated with Emerging MDR
2.4. Risk Factors Associated with FI
2.5. Risk Factors Associated with Overall IPN
2.6. Mortality and ICU Admission Rate Analysis
3. Discussion
4. Materials and Methods
4.1. Study Population
4.2. Definitions
4.3. Microbiological Cultures and Antibiotics
4.4. Primary Endpoint
4.5. Secondary Endpoints
4.6. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Iannuzzi, J.P.; King, J.A.; Leong, J.H.; Quan, J.; Windsor, J.W.; Tanyingoh, D.; Coward, S.; Forbes, N.; Heitman, S.J.; Shaheen, A.A.; et al. Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. Gastroenterology 2022, 162, 122–134. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Petrov, M.S.; Yadav, D. Global epidemiology and holistic prevention of pancreatitis. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 175–184. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sahu, S.K.; Giri, S.; Das, S.; Patro, C.D.; Praharaj, D.L.; Mallick, B.; Nath, P.; Panigrahi, S.C.; Anand, A.C. Approach to the Diagnosis and Management of Infected Pancreatic Necrosis: A Narrative Review. Cureus 2025, 17, e83020. [Google Scholar] [CrossRef] [Scilit]
- Shah, J.; Fernandez, Y.V.M.; Jagodzinski, R.; Arvanitakis, M. Infected pancreatic necrosis-Current trends in management. Indian J. Gastroenterol. 2024, 43, 578–591. [Google Scholar] [CrossRef] [Scilit]
- Boxhoorn, L.; van Dijk, S.M.; van Grinsven, J.; Verdonk, R.C.; Boermeester, M.A.; Bollen, T.L.; Bouwense, S.A.W.; Bruno, M.J.; Cappendijk, V.C.; Dejong, C.H.C.; et al. Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis. N. Engl. J. Med. 2021, 385, 1372–1381. [Google Scholar] [CrossRef] [Scilit]
- Hu, W.M.; Hua, T.R.; Zhang, Y.L.; Chen, G.R.; Song, K.; Pendharkar, S.; Wu, D.; Windsor, J.A. Prognostic significance of organ failure and infected pancreatic necrosis in acute pancreatitis: An updated systematic review and meta-analysis. J. Dig. Dis. 2023, 24, 648–659. [Google Scholar] [CrossRef] [Scilit]
- Podda, M.; Pellino, G.; Di Saverio, S.; Coccolini, F.; Pacella, D.; Cioffi, S.P.B.; Virdis, F.; Balla, A.; Ielpo, B.; Pata, F.; et al. Infected pancreatic necrosis: Outcomes and clinical predictors of mortality. A post hoc analysis of the MANCTRA-1 international study. Updates Surg. 2023, 75, 493–522. [Google Scholar] [CrossRef] [Scilit]
- Li, X.Y.; He, C.; Zhu, Y.; Lu, N.H. Role of gut microbiota on intestinal barrier function in acute pancreatitis. World J. Gastroenterol. 2020, 26, 2187–2193. [Google Scholar] [CrossRef] [Scilit]
- Baron, T.H.; DiMaio, C.J.; Wang, A.Y.; Morgan, K.A. American Gastroenterological Association Clinical Practice Update: Management of Pancreatic Necrosis. Gastroenterology 2020, 158, 67–75.e61. [Google Scholar] [CrossRef] [Scilit]
- Arvanitakis, M.; Dumonceau, J.M.; Albert, J.; Badaoui, A.; Bali, M.A.; Barthet, M.; Besselink, M.; Deviere, J.; Oliveira Ferreira, A.; Gyökeres, T.; et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy 2018, 50, 524–546. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society. Pancreatology 2025, 25, 770–814. [CrossRef] [Scilit]
- Mouli, V.P.; Sreenivas, V.; Garg, P.K. Efficacy of conservative treatment, without necrosectomy, for infected pancreatic necrosis: A systematic review and meta-analysis. Gastroenterology 2013, 144, 333–340.e332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Timmerhuis, H.C.; van den Berg, F.F.; Noorda, P.C.; van Dijk, S.M.; van Grinsven, J.; Sperna Weiland, C.J.; Umans, D.S.; Mohamed, Y.A.; Curvers, W.L.; Bouwense, S.A.W.; et al. Overuse and Misuse of Antibiotics and the Clinical Consequence in Necrotizing Pancreatitis: An Observational Multicenter Study. Ann. Surg. 2023, 278, e812–e819. [Google Scholar] [CrossRef] [Scilit]
- Lu, J.; Ding, Y.; Qu, Y.; Mei, W.; Guo, Y.; Fang, Z.; Qu, C.; Gao, C.; Cao, F.; Li, F.; et al. Risk Factors and Outcomes of Multidrug-Resistant Bacteria Infection in Infected Pancreatic Necrosis Patients. Infect. Drug Resist. 2022, 15, 7095–7106. [Google Scholar] [CrossRef] [Scilit]
- Chesdachai, S.; Yetmar, Z.A.; Lahr, B.D.; Vege, S.S.; Vergidis, P. Clinical characteristics and outcomes of pancreatic fungal infection in patients with necrotizing pancreatitis. Med. Mycol. 2023, 61, myad068. [Google Scholar] [CrossRef] [Scilit]
- Singh, R.R.; Mitchell, W.; David, Y.; Cheesman, A.; Dixon, R.E.; Nagula, S.; DiMaio, C.J.; Greenwald, D.A.; Kumta, N.A. Pancreatic Fungal Infection in Patients With Necrotizing Pancreatitis: A Systematic Review and Meta-analysis. J. Clin. Gastroenterol. 2021, 55, 218–226. [Google Scholar] [CrossRef] [Scilit]
- Ning, C.; Huang, G.; Shen, D.; Bonsu, A.; Ji, L.; Lin, C.; Cao, X.; Li, J. Adverse clinical outcomes associated with multidrug-resistant organisms in patients with infected pancreatic necrosis. Pancreatology 2019, 19, 935–940. [Google Scholar] [CrossRef] [Scilit]
- Moka, P.; Goswami, P.; Kapil, A.; Xess, I.; Sreenivas, V.; Saraya, A. Impact of Antibiotic-Resistant Bacterial and Fungal Infections in Outcome of Acute Pancreatitis. Pancreas 2018, 47, 489–494. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jain, S.; Mahapatra, S.J.; Gupta, S.; Shalimar; Garg, P.K. Infected Pancreatic Necrosis due to Multidrug-Resistant Organisms and Persistent Organ failure Predict Mortality in Acute Pancreatitis. Clin. Transl. Gastroenterol. 2018, 9, 190. [Google Scholar] [CrossRef] [Scilit]
- Li, X.; Li, L.; Liu, L.; Hu, Y.; Zhao, S.; Sun, J.; Wang, G.; Hai, X. Risk Factors of Multidrug Resistant Pathogens Induced Infection in Severe Acute Pancreatitis. Shock 2020, 53, 293–298. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, D.; Xiao, J.; Ding, J.; Jia, Y.; Guo, Z.; Liu, H.; Peng, J. Predictors of Mortality and Drug Resistance Among Carbapenem-Resistant Enterobacteriaceae-Infected Pancreatic Necrosis Patients. Infect. Dis. Ther. 2021, 10, 1665–1676. [Google Scholar] [CrossRef] [Scilit]
- Arvanitakis, M.; Ockenga, J.; Bezmarevic, M.; Gianotti, L.; Krznarić, Ž.; Lobo, D.N.; Löser, C.; Madl, C.; Meier, R.; Phillips, M.; et al. ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis. Clin. Nutr. 2024, 43, 395–412. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fostier, R.; Arvanitakis, M.; Gkolfakis, P. Nutrition in acute pancreatitis: When, what and how. Curr. Opin. Clin. Nutr. Metab. Care 2022, 25, 325–328. [Google Scholar] [CrossRef] [Scilit]
- Arulkumaran, N.; Routledge, M.; Schlebusch, S.; Lipman, J.; Conway Morris, A. Antimicrobial-associated harm in critical care: A narrative review. Intensive Care Med. 2020, 46, 225–235. [Google Scholar] [CrossRef] [Scilit]
- Al-Omran, M.; Albalawi, Z.H.; Tashkandi, M.F.; Al-Ansary, L.A. Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst. Rev. 2010, 2010, Cd002837. [Google Scholar] [CrossRef] [Scilit]
- Yao, H.; He, C.; Deng, L.; Liao, G. Enteral versus parenteral nutrition in critically ill patients with severe pancreatitis: A meta-analysis. Eur. J. Clin. Nutr. 2018, 72, 66–68. [Google Scholar] [CrossRef] [Scilit]
- Wu, L.M.; Sankaran, S.J.; Plank, L.D.; Windsor, J.A.; Petrov, M.S. Meta-analysis of gut barrier dysfunction in patients with acute pancreatitis. Br. J. Surg. 2014, 101, 1644–1656. [Google Scholar] [CrossRef] [Scilit]
- Horibe, M.; Sanui, M.; Sasaki, M.; Honda, H.; Ogura, Y.; Namiki, S.; Sawano, H.; Goto, T.; Ikeura, T.; Takeda, T.; et al. Impact of Antimicrobial Prophylaxis for Severe Acute Pancreatitis on the Development of Invasive Candidiasis: A Large Retrospective Multicenter Cohort Study. Pancreas 2019, 48, 537–543. [Google Scholar] [CrossRef] [Scilit]
- Li, F.; Zhang, F.; Wan, X.; Wu, K.; Liu, Q.; Qiu, C.; Yin, H.; Lyu, J. Infections in Acute Pancreatitis: Organisms, Resistance-Patterns and Effect on Mortality. Dig. Dis. Sci. 2023, 68, 630–643. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fan, N.; Hu, Y.; Shen, H.; Liu, S.; Zhao, G.; Sun, L.; Li, C.; Zhao, X.; Li, Y.; Wang, J.; et al. Compositional and drug-resistance profiling of pathogens in patients with severe acute pancreatitis: A retrospective study. BMC Gastroenterol. 2020, 20, 405. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lu, J.D.; Cao, F.; Ding, Y.X.; Wu, Y.D.; Guo, Y.L.; Li, F. Timing, distribution, and microbiology of infectious complications after necrotizing pancreatitis. World J. Gastroenterol. 2019, 25, 5162–5173. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sahar, N.; Kozarek, R.A.; Kanji, Z.S.; Chihara, S.; Gan, S.I.; Irani, S.; Larsen, M.; Ross, A.S.; Gluck, M. The microbiology of infected pancreatic necrosis in the era of minimally invasive therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 1353–1359. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Büchler, M.; Malfertheiner, P.; Friess, H.; Isenmann, R.; Vanek, E.; Grimm, H.; Schlegel, P.; Friess, T.; Beger, H.G. Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology 1992, 103, 1902–1908. [Google Scholar] [CrossRef] [Scilit]
- Racketa, S.; Gandhi, K.; Lambie, M. Meropenem versus piperacillin-tazobactam for the treatment of pancreatic necrosis. Diagn. Microbiol. Infect. Dis. 2024, 109, 116209. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Maguire, C.; Agrawal, D.; Daley, M.J.; Douglass, E.; Rose, D.T. Rethinking Carbapenems: A Pharmacokinetic Approach for Antimicrobial Selection in Infected Necrotizing Pancreatitis. Ann. Pharmacother. 2021, 55, 902–913. [Google Scholar] [CrossRef] [Scilit]
- Otto, W.; Komorzycki, K.; Krawczyk, M. Efficacy of antibiotic penetration into pancreatic necrosis. HPB 2006, 8, 43–48. [Google Scholar] [CrossRef] [Scilit]
- Siriwardena, A.K.; Jegatheeswaran, S.; Mason, J.M. A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): A single-centre, patient-blinded, randomised controlled trial. Lancet Gastroenterol. Hepatol. 2022, 7, 913–921. [Google Scholar] [CrossRef] [Scilit]
- Banks, P.A.; Bollen, T.L.; Dervenis, C.; Gooszen, H.G.; Johnson, C.D.; Sarr, M.G.; Tsiotos, G.G.; Vege, S.S. Classification of acute pancreatitis—2012: Revision of the Atlanta classification and definitions by international consensus. Gut 2013, 62, 102–111. [Google Scholar] [CrossRef] [Scilit]
- Borens, B.; Arvanitakis, M.; Absil, J.; El Bouchaibi, S.; Matos, C.; Eisendrath, P.; Toussaint, E.; Deviere, J.; Bali, M.A. Added value of diffusion-weighted magnetic resonance imaging for the detection of pancreatic fluid collection infection. Eur. Radiol. 2017, 27, 1064–1073. [Google Scholar] [CrossRef] [Scilit]
- Baroud, S.; Chandrasekhara, V.; Storm, A.C.; Law, R.J.; Vargas, E.J.; Levy, M.J.; Mahmoud, T.; Bazerbachi, F.; Bofill-Garcia, A.; Ghazi, R.; et al. Novel classification system for walled-off necrosis: A step toward standardized nomenclature and risk-stratification framework. Gastrointest. Endosc. 2023, 97, 300–308. [Google Scholar] [CrossRef] [Scilit]
- van Baal, M.C.; Bollen, T.L.; Bakker, O.J.; van Goor, H.; Boermeester, M.A.; Dejong, C.H.; Gooszen, H.G.; van der Harst, E.; van Eijck, C.H.; van Santvoort, H.C.; et al. The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. Surgery 2014, 155, 442–448. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef] [Scilit] [PubMed]




| Characteristic | WON Acute Pancreatitis Cohort (N = 71) |
|---|---|
| Age, years [95% CI] | 51 ± 16 [48–55] |
| Male sex, n (%) | 51 (72) |
| Cause of pancreatitis, n (%) | |
| 27 (38) 23 (33) 15 (21) 3 (4) 2 (3) 1 (1) |
| Disease severity, n (%) | |
| 39(55)/32(45) 39 (55) 21 (30) 38 (56) 26 (38) 29 (43) |
| CT Severity Index score on admission, n (%) ‡ | 6 ± 3 [5–7] |
| Extent of pancreatic necrosis on admission, n (%) ‡ | |
| 41 (59) 13 (19) 15 (22) |
| Diabetes, n (%) | 20 (28.2) |
| Body mass index, kg/m2 [95% CI] | 28 ± 5 [26–29] |
| Proton-pump inhibitor therapy, n (%) | 65 (91.5) |
| Diagnosis of infected pancreatic necrosis ¶, n (%) | 54 (76) |
| Interventions related to infected pancreatic necrosis, n (%) | |
| 71 (100) 25 (35) 14 (20) 10 (14) 4 (6) |
| No. of days from onset of symptoms to diagnosis of ANP §, days, median (IQR) | 5 (2–8) |
| No. of days from onset of symptoms to diagnosis of IPN, days, median (IQR) | 36 (24–69) |
| Nutritional support, n (%) | 46 (65) |
| 15 (21) 10 (14) 21 (30) |
| Length of stay, days, median (IQR) | 58 (41–91) |
| Mortality, n (%) | 13 (18) |
| Characteristic | WON Acute Pancreatitis Cohort (N = 71) |
|---|---|
| Prior exposure to antibiotics, n (%) | 56 (79) |
| No. of prior antibiotics, n (%) | |
| 15 (21) 29 (41) 27 (38) |
| Prior antifungal therapy, n (%) ‡ | 6 (8.5) |
| Type of antibiotic therapy before the first intervention, n (%) §, | |
| 26 (28) 30 (33) 14 (15) 4 (4) 1 (1) 1 (1) 16 (18) 5 3 8 |
| Documentation of prior antimicrobial therapy, n (%) §, | |
| 67 (73) 25 (27) 4 12 2 2 5 |
| No. of days of previous antibiotic therapy, median (IQR) | 7 (2–18) |
| No. of patients free of antibiotics > 7 days before drainage | 31 (44) |
| CRP (mg/dl); day before drainage, mean [95% CI] | 123 ± 104 [98–148] |
| Fever (T° > 38.5 °C); day before drainage, n (%) | 28 (39.4) |
| WBC count; day before drainage (× 103/mm3) | 10.7 ± 6.3 [9.2–12.2] |
| Systemic inflammatory response syndrome, n (%) | 21 (29.6) |
| Characteristic | WON Acute Pancreatitis Cohort (N = 71) |
|---|---|
| No. of patients with IPN (confirmed/suspected), n (%) | 52 (73%)/2 (3%) |
| No. of patients with antibiotic after 1st intervention, n (%) | 70 (99) |
| Type of antibiotic therapy after the first intervention, n (%) † | |
| 24 (34) 22 (32) 12 (17) 2 (3) 10 (14) 2 2 6 |
| Accuracy of 1st antibiotic based on 1st bacteriological sample, n (%) | 51 (73) |
| Antifungal therapy, n (%) § | 31 (44) |
| No. of antibiotic adaptations per patient, median IQR | 2 [1–4] |
| No. of different antimicrobial therapies per patient, median (IQR) | 4 [2–6] |
| Total duration of antibiotic therapy, days, [95% CI] | 43 ± 30 [36–51] |
| Univariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|
| Variable | OR [95% CI] | p-Value | Variable | b [95% CI] | p-Value |
| Age | 0.99 [0.96–1.02] | 0.642 | |||
| Prior exposure to ATB | 3.67 [1.11–14.54] | 0.040 | |||
| Changes in ATB | 1.82 [1.34–2.64] | 0.0005 | Changes in ATB | 1.70 [1.18–2.43] | 0.004 |
| ICU admission | 4.44 [1.63–12.96] | 0.0046 | |||
| Size collection (length) | 1.01 [1.0–1.02] | 0.0466 | |||
| Size collection (width) | 1.01 [1–1.02] | 0.058 | |||
| Type 2 diabetes status | 1.69 [0.60–4.97] | 0.329 | |||
| PPI | 5.83 [0.87–115.0] | 0.116 | |||
| BMI >30 | 1.36 [0.49–3.83] | 0.550 | |||
| Nutritional support | 8.27 [2.76–28.9] | 0.0003 | Nutritional support | 5.69 [1.52–20.50] | 0.010 |
| AP duration | 1.04 [1.02–1.06] | 0.0004 | |||
| Albumin (g/L) | 0.92 [0.84–0.99] | 0.027 | |||
| Prealbumin (mg/L) | 0.95 [0.86–1.04] | 0.284 | |||
| Number of necrosectomies ≥ 3 | 4.71 [1.07–32.96] | 0.062 | |||
| Number of total procedures ≥ 5 | 8.4 [2.81–29.31] | 0.0003 | |||
| Univariate Analysis | ||
|---|---|---|
| Variable | OR [95% CI] | p-Value |
| Age | 1.03 [0.99–1.06] | 0.135 |
| Prior exposure to ATB | 1.20 [0.35–4.81] | 0.781 |
| Changes in ATB | 1.17 [0.91–1.51] | 0.219 |
| ICU admission | 2.69 [0.88–9.37] | 0.096 |
| Size collection (length) | 1.00 [0.99–1.01] | 0.591 |
| Size collection (width) | 1.01 [1.00–1.02] | 0.192 |
| Type 2 diabetes status | 1.95 [0.64–5.84] | 0.232 |
| PPI | 0.83 [0.15–6.32] | 0.833 |
| BMI >30 | 0.80 [0.25–2.39] | 0.696 |
| Nutritional support | 3.08 [0.97–11.89] | 0.051 |
| AP duration | 1.00 [0.99–1.01] | 0.459 |
| Albumin (g/L) | 0.93 [0.85–1.01] | 0.111 |
| Prealbumin (mg/L) | 0.97 [0.87–1.07] | 0.563 |
| Number of necrosectomies ≥ 3 | 2.81 [0.70–11.40] | 0.138 |
| Number of total procedures ≥ 5 | 3.43 [1.20–10.22] | 0.023 |
| Univariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|
| Variable | OR [95% CI] | p-Value | Variable | b [95% CI] | p-Value |
| Age | 1.02 [0.99–1.06] | 0.198 | |||
| Prior exposure to ATB | 9.00 [2.59–34.27] | 0.0007 | Prior exposure to ATB | 26.41 [1.90–366.38] | 0.015 |
| Changes in ATB | 1.60 [1.14–2.41] | 0.014 | |||
| ICU admission | 4.80 [1.52–17.21] | 0.010 | |||
| Size collection (length) | 1.00 [0.99–1.01] | 0.823 | |||
| Size collection (width) | 1.01 [1–1.02] | 0.160 | |||
| Type 2 diabetes status | 0.92 [0.29–3.30] | 0.896 | |||
| PPI | 8.00 [1.41–62.45] | 0.024 | |||
| BMI >30 | 1.17 [0.37–4.15] | 0.801 | |||
| Nutritional support | 3.71 [1.21–12.02] | 0.023 | |||
| AP duration | |||||
| Albumine (g/L) | 0.76 [0.66–0.86] | <0.0001 | |||
| Prealbumin (mg/L) | 0.83 [0.71–0.93] | 0.0035 | Prealbumin (mg/L) | 0.77 [0.63–0.94] | 0.012 |
| Number of necrosectomies ≥ 3 | 0.72 [0.62–0.84] | 0.052 | |||
| Number of total procedures ≥ 5 | 3.46 [0.99–16.29] | 0.073 | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Fernandez Y Viesca, M.; Hadefi, A.; Otero Sanchez, L.; Pezzullo, M.; Van Wettere, M.; Karakike, E.; Hites, M.; De Maertelaer, V.; Delhaye, M.; Arvanitakis, M. Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis. Antibiotics 2026, 15, 220. https://doi.org/10.3390/antibiotics15020220
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L, Pezzullo M, Van Wettere M, Karakike E, Hites M, De Maertelaer V, Delhaye M, Arvanitakis M. Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis. Antibiotics. 2026; 15(2):220. https://doi.org/10.3390/antibiotics15020220
Chicago/Turabian StyleFernandez Y Viesca, Michael, Alia Hadefi, Lukas Otero Sanchez, Martina Pezzullo, Morgane Van Wettere, Eleni Karakike, Maya Hites, Viviane De Maertelaer, Myriam Delhaye, and Marianna Arvanitakis. 2026. "Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis" Antibiotics 15, no. 2: 220. https://doi.org/10.3390/antibiotics15020220
APA StyleFernandez Y Viesca, M., Hadefi, A., Otero Sanchez, L., Pezzullo, M., Van Wettere, M., Karakike, E., Hites, M., De Maertelaer, V., Delhaye, M., & Arvanitakis, M. (2026). Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis. Antibiotics, 15(2), 220. https://doi.org/10.3390/antibiotics15020220

